Literature DB >> 11986397

Molecular aspects of melanocytic dysplastic nevi.

Mahmoud Rezk Abd-Elwahed Hussein1, Gary Stewart Wood.   

Abstract

Melanocytic dysplastic nevi were first described in both patients and their relatives who had one or several cutaneous malignant melanomas. Most of these dysplastic lesions are biologically stable, but some of them have severe histological atypia and can progress further to melanomas. Although several studies have suggested the etiological importance of dysplastic nevi in the development of melanomas, comprehensive reviews of the molecular changes in these dysplastic lesions are still scarce. To remedy this issue, this article analyzes the available molecular information about dysplastic nevi and provides the current state of knowledge regarding the karyotypic abnormalities of the melanoma/dysplastic nevus trait and the involvement of allelic loss, tumor suppressor genes, mismatch repair proteins, microsatellite instability, oncogenes, extracellular matrix proteins, and growth factors in the genesis of these lesions. These studies suggest that although some of these lesions represent "genetic dead-ends," others represent intermediate lesional steps in the melanoma tumorigenesis pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986397      PMCID: PMC1906986          DOI: 10.1016/S1525-1578(10)60684-8

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  139 in total

1.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

Authors:  L R Livingstone; A White; J Sprouse; E Livanos; T Jacks; T D Tlsty
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

Review 2.  NIH Consensus conference. Diagnosis and treatment of early melanoma.

Authors: 
Journal:  JAMA       Date:  1992-09-09       Impact factor: 56.272

3.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

4.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

Authors:  Y Yin; M A Tainsky; F Z Bischoff; L C Strong; G M Wahl
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

5.  Expression of mutant p53 in melanoma.

Authors:  J R Stretch; K C Gatter; E Ralfkiaer; D P Lane; A L Harris
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

6.  Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees.

Authors:  D J Nancarrow; J M Palmer; M K Walters; B M Kerr; G J Hafner; L Garske; G R McLeod; N K Hayward
Journal:  Genomics       Date:  1992-01       Impact factor: 5.736

7.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 8.  p53: the ultimate tumor suppressor gene?

Authors:  M Oren
Journal:  FASEB J       Date:  1992-10       Impact factor: 5.191

9.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.

Authors:  L A Cannon-Albright; D E Goldgar; L J Meyer; C M Lewis; D E Anderson; J W Fountain; M E Hegi; R W Wiseman; E M Petty; A E Bale
Journal:  Science       Date:  1992-11-13       Impact factor: 47.728

10.  Homozygous deletions within human chromosome band 9p21 in melanoma.

Authors:  J W Fountain; M Karayiorgou; M S Ernstoff; J M Kirkwood; D R Vlock; L Titus-Ernstoff; B Bouchard; S Vijayasaradhi; A N Houghton; J Lahti
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more
  8 in total

1.  Expression of Bcl-2, Melan A and HMB-45 in Dysplastic Nevi.

Authors:  Oana Maria Patrascu; Mariana Costache; Adrian Vasile Dumitru; Corina Nicoleta Mehotin; Maria Sajin; Anca Mihaela Lazaroiu
Journal:  Maedica (Bucur)       Date:  2016-03

Review 2.  My approach to atypical melanocytic lesions.

Authors:  K S Culpepper; S R Granter; P H McKee
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

Review 3.  The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

Authors:  Boris C Bastian
Journal:  Annu Rev Pathol       Date:  2014       Impact factor: 23.472

Review 4.  [The dysplastic nevus. Separate entity, melanoma precursor or diagnostic dilemma?].

Authors:  A Roesch; M Landthaler; T Vogt
Journal:  Hautarzt       Date:  2003-09       Impact factor: 0.751

Review 5.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

6.  Molecular nevogenesis.

Authors:  Andrew L Ross; Margaret I Sanchez; James M Grichnik
Journal:  Dermatol Res Pract       Date:  2011-04-06

7.  Cellular senescence in naevi and immortalisation in melanoma: a role for p16?

Authors:  V C Gray-Schopfer; S C Cheong; H Chong; J Chow; T Moss; Z A Abdel-Malek; R Marais; D Wynford-Thomas; D C Bennett
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

8.  ABO and Rhesus blood groups and risk of endometriosis in a French Caucasian population of 633 patients living in the same geographic area.

Authors:  Bruno Borghese; Mélanie Chartier; Carlos Souza; Pietro Santulli; Marie-Christine Lafay-Pillet; Dominique de Ziegler; Charles Chapron
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.